Engflag

Cefi

Quick links to important sections

Cefi

Cefi_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefi

Property Description
Active ingredient Cefixime
Form Tablets, Capsules, Oral Suspension
Pharmacological class Antibiotic (Third-Generation Cephalosporin)
General purpose Anti-infective agent (Bactericidal)
Origin Semisynthetic

What Type of Medicine is Cefi (Cefixime)?

The medicinal preparation Cefi is a prescription-only medicine whose single active ingredient is Cefixime. This compound is classified as an antibiotic, belonging to the cephalosporin family. Cefixime is distinctly categorized as a third-generation cephalosporin, which signifies its specialized, broad-spectrum structure. This classification, clinically recognized for its improved stability against certain bacterial enzymes, ensures its efficacy against a wider range of bacteria compared to earlier generations. Cefixime is a semisynthetic compound, meaning it is manufactured by chemically modifying the core structure derived from the 7-aminocephalosporanic acid nucleus. Popular alternative brands containing Cefixime include Suprax and Taxim-O.

Composition, Available Forms, and General Purpose

Cefi primarily contains Cefixime trihydrate as its key active component, combined with necessary pharmaceutical excipients required for the final product. As an antibiotic, its general purpose is to act as a bactericidal agent, directly killing susceptible bacteria to resolve infections. Cefixime is effective due to its high and sustained concentrations after oral administration. This means the medicine is well-absorbed when taken by mouth and is reliably distributed to eliminate the bacteria, making it a common choice for empirical therapy against bacterial illness. Cefixime is manufactured in several convenient oral dosage forms, including compressed tablets, capsules, and a powder for oral suspension. The suspension form is often positioned for pediatric patients, providing a reliable option for younger individuals.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Cefi?

Possible side effects and safety information

The official safety profile for Cefi (Cefixime), as established in regulatory documents, classifies potential adverse reactions based on their frequency and the system they affect. The medicine is contraindicated in patients with known hypersensitivity to the active substance, other cephalosporins, or any excipients. Caution is noted in individuals with a history of penicillin allergy due to the risk of cross-hypersensitivity.

Adverse Reaction Classification

The most frequently documented effects are categorized as Common, primarily involving Gastrointestinal Disorders. These include diarrhea, loose stools, nausea, and abdominal pain. Less common reactions may affect the skin (e.g., rash, pruritus) and the nervous system (e.g., headache, dizziness).

Serious Adverse Reactions and Systemic Effects

Regulatory labeling specifies rare but clinically significant adverse reactions. These include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome, and severe allergic reactions like anaphylaxis. Postmarketing surveillance also documents the potential for pseudomembranous colitis (a severe form of diarrhea) and transient changes in blood cell counts and liver enzyme levels.

Population and Exposure Safety Notes

Specific safety considerations apply to certain patient groups. Individuals with renal impairment (kidney function decline) require a dose adjustment to mitigate the risk of adverse neurological effects. The safety and efficacy of Cefixime have not been established in pediatric patients under six months of age. Furthermore, regulatory texts note that superinfection—the overgrowth of non-susceptible organisms—may occur following a prolonged course of therapy.

Overdose and Emergency Response

Overdose and when to seek help

Documented Manifestations and Severe Risks

Overdose manifestations at high single doses are officially reported to not differ significantly from the adverse effects observed at therapeutic doses, with gastrointestinal symptoms being common. The principal severe risk documented is beta-lactam induced neurotoxicity, which may present as seizures, myoclonus, and encephalopathy. Patients with impaired renal function are at a significantly higher risk for this neurotoxicity due to delayed drug clearance, and specific attention must be paid to this population.

Regulator-Mandated Emergency Actions and Management

Immediate medical attention must be sought in all cases of suspected overdose; consultation with a Poison Control Center is also officially recommended. Management is defined as symptomatic and supportive treatment, as no specific antidote is known. Continuous patient observation is required for at least 24 hours to monitor for delayed adverse effects and the development of neurological symptoms. Furthermore, hemodialysis and peritoneal dialysis are officially stated as ineffective treatment options. Cefixime is also documented to cause false-positive reactions when testing for ketones or glucose in the urine.

Therapeutic Uses of Cefi

What Cefi Treats: Main Uses and Benefits

Cefi is commonly used across conditions presenting with systemic or localized discomfort associated with acute or disruptive episodes. The medication is applied across therapeutic domains where short-term symptomatic assistance is needed, relevant for easing symptoms that interfere with daily functioning. Cefixime is used to treat certain infections caused by bacteria.

Easing Symptoms Related to Systemic Imbalance

Cefi is applied across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, particularly those linked to heightened physiological activity. This supports patients during episodes of heightened discomfort and helps improve day-to-day comfort during symptomatic periods.

Supporting Stability in Fluctuating Condition Patterns

This medicine is relevant in conditions characterized by periods of heightened symptoms or recurrent manifestations where functional stability becomes affected. It is often used when symptoms intensify, providing supportive relief that contributes to easing the overall symptom load.

Quick Fact: Cefi is commonly used to help manage symptoms that create noticeable physiological strain in situations involving episodic manifestations.

Regulatory References

  1. Cefixime is used to treat certain infections caused by bacteria

Eligibility and Restrictions for Use

This section summarizes the official eligibility and non-eligibility information for Cefi (cefixime) as defined by authoritative governmental regulatory documents.

Contraindicated Populations

Cefi is absolutely prohibited for use in individuals with a known hypersensitivity (allergy) to cefixime or to any antibiotic belonging to the cephalosporin class. Caution is also advised due to documented cross-reactivity with penicillins.

Age and Physiological State

Population Group Eligibility Status (Regulatory)
Infants (< 6 months) Safety and efficacy have not been established.
Children (≥ 6 months) Allowed. Generally treated with an age/weight-based dose.
Pregnancy Use only if clearly needed; insufficient data from controlled human studies.
Lactation Consideration should be given to discontinuing nursing temporarily.

Eligibility-Related Restrictions

Use is restricted in patients with impaired renal function (Creatinine Clearance < 60 mL/min), requiring specific dose adjustment to prevent accumulation. Patients with Phenylketonuria (PKU) should avoid the chewable tablet form due to its phenylalanine content. Patients with a history of colitis or other serious gastrointestinal disease should use Cefi with caution.

What should I know about interactions with other medicines?

Cefi Interactions with other medicines and products

The official interaction profile for Cefixime is primarily defined by its effects on co-administered medications and its interference with specific laboratory tests.

Property Regulatory Documentation Statement
Medicinal product categories with documented interactions Anticoagulants (Coumarin-type), Renal Tubular Secretion Inhibitors, Oral Contraceptives, Calcium Channel Blockers (Nifedipine), High-Dose Salicylates, Diabetic Urine Testing Products.
Specific interacting medicines (if explicitly listed) Warfarin, Carbamazepine, Probenecid, Nifedipine, Hormonal Contraceptives.
Mechanistic basis of interactions (only if stated in label) Interaction with Probenecid involves the reduction of Cefixime's renal clearance. The interaction with oral contraceptives is associated with a potential alteration of the gut flora.
Timing-based interaction rules (if applicable) No mandatory timing requirements are specified for co-administered products. Administration with food officially delays the time to maximal absorption (T max).
Population-specific interaction notes (if applicable) The risk of prothrombin time prolongation is officially noted to be increased in patients concurrently with renal impairment, hepatic impairment, or poor nutritional state.
Interaction-related restrictions Potential for false-positive results exists for urine glucose tests that utilize cupric sulfate solutions and for the Direct Coombs test.

Official Interaction Statements

  • Co-administration with coumarin-type anticoagulants, such as Warfarin, is documented to increase the risk of prothrombin time prolongation.
  • Elevated plasma concentrations of Carbamazepine have been reported when co-administered.
  • Probenecid is documented to increase Cefixime's systemic exposure (AUC and C max) by decreasing its renal clearance.
  • The administration may reduce the documented effectiveness of hormonal contraceptives (oral type).
  • Nifedipine is documented to increase the oral bioavailability of Cefixime.

Regulatory documents define Cefixime's interaction structure through multiple categories of exposure and pharmacodynamic effects, particularly focusing on the reinforcement of anticoagulant activity. The profile includes substances that officially modify Cefixime's own concentration, such as Probenecid and Nifedipine, and lists several drugs whose systemic levels are altered by Cefixime. The structure is completed by constraints regarding interference with specific laboratory diagnostic assays.

Mechanism of Action

The mechanism of Cefixime is highly specialized, focusing exclusively on essential structures unique to the bacterial cell, thereby establishing its effect as bactericidal.

Inhibiting Essential Bacterial Cell Wall Assembly

Cefixime functions by acting as an irreversible inhibitor of crucial bacterial enzymes known as Penicillin-Binding Proteins (PBPs), particularly PBP 3. The drug forms a stable, covalent bond with these enzymes, immediately halting their ability to perform transpeptidation, the final and essential step in building the rigid, cross-linked peptidoglycan layer of the cell wall. This molecular intervention directly prevents the assembly of a structurally sound cell wall.

Inducing Osmotic Lysis and Eliminating Pathogens

The resulting structurally defective cell wall is unable to counteract the high internal osmotic pressure of the bacterial cell. This mechanistic cascade leads to the influx of water and subsequent rupture (lysis) of the bacterial cell, resulting in its destruction. This lytic action establishes the physiological effect that characterizes the Cefixime mechanism.

Mechanistic Constraints and Resistance

While its inherent stability against many bacterial enzymes is a mechanistic feature, its function is limited by bacterial adaptation. This includes the potential for pathogens to structurally alter their PBP targets to reduce drug affinity, or to overexpress specialized Efflux Pumps that actively remove Cefixime before it can reach its target enzyme, thereby reducing the inhibitory effect.

Dosage and Administration Information

How to Use Cefi — Official Administration Guidelines

The correct use of this medicine is strictly defined by official regulatory documentation, covering the route, dosing, preparation, and duration.

Administration Scope

  • Route of Administration: The medicine is administered orally (by mouth).
  • Timing in Relation to Meals: It may be taken with or without food.
  • Dosing Schedule: The recommended daily dose for adults and children over 12 years of age or weighing more than 45 kg is 400 mg daily. This dose may be taken as a single 400 mg tablet or capsule once a day, or it may be divided and taken as 200 mg every 12 hours.

Special Dosing and Preparation Instructions

Patient Group/Condition Dosing or Procedural Rule
Pediatric Patients (6 months to 12 years) Dosing is weight-based, typically 8 mg/ kg/ day of the oral suspension, administered once daily or divided every 12 hours. Children over 45 kg should receive the adult dose.
Renal Impairment A dose adjustment is required for adult patients with severe kidney function impairment (creatinine clearance <20 mL/ min), where the recommended dose is 200 mg once daily.
Oral Suspension The bottle must be shaken well before each use. The dose should be measured using a calibrated measuring device.
Chewable Tablets Chewable tablets must be chewed or crushed before swallowing.
Duration of Therapy Treatment must be continued for the full prescribed duration, which is at least 10 days for certain infections, even if the patient feels better sooner.

Missed Dose Instructions

If a dose is missed, take it as soon as you remember. However, if it is almost time for the next scheduled dose, skip the missed dose and return to the regular dosing schedule. Do not take two doses at the same time.

Recent Clinical Evidence

Research evidence / Overview of studies for Cefi

This section describes the types of clinical studies conducted to evaluate Cefixime, what researchers monitored in those trials, and what remains unclear in the research record, according to regulatory and scientific summaries.

Evidence for Urinary Tract Infections and Respiratory Infections

Research examined Cefixime in clinical trials for bacterial conditions, including uncomplicated urinary tract infections (UTI) and acute exacerbations of chronic bronchitis (AECB). These trials were evaluated in research exploring how symptoms change over time and to monitor the clearance of the specific bacteria causing the infection. Researchers primarily measured two outcomes: clinical cure (meaning the resolution of physical symptoms) and bacteriological cure (meaning confirmation that the bacteria were no longer present). Findings describe patterns observed in studies exploring how symptoms change over time in the observed populations for AECB.

Evidence for Otitis Media (Middle Ear Infection)

Cefixime was studied for the treatment of acute otitis media. The evidence base is derived from randomized, open-label, multicenter clinical trials primarily involving pediatric patients (children six months and older). The study outcomes examined included measuring clinical success, defined as the cure or improvement of episodic or acute changes in symptoms like fever and ear pain. Regulatory analyses have described that the observed response rates for Cefixime against certain organisms, like Streptococcus pneumoniae, may not have been sustained against all studied comparators. Data for children younger than six months of age remain insufficient.

Evidence for Uncomplicated Gonorrhea and Research Gaps

Cefixime was evaluated in studies for treating uncomplicated gonorrhea, relying on single-dose randomized controlled trials and public health monitoring that tracked the rate of microbiological cure. Historically, trials reported measurements of microbiological cure for urogenital infections. However, research observed less consistent findings for infections at the pharyngeal site. The ongoing pattern of reduced bacterial susceptibility observed in research is a critical factor, necessitating continuous monitoring of its performance in the field. Long-term effects are not fully established through these trials; for instance, research does not include data establishing the prevention of long-term complications like rheumatic fever.

Frequently Asked Questions (FAQ)

Common questions about Cefi (FAQ)

Q: What kind of conditions is Cefi approved to treat?

Cefixime is officially indicated for treating specific bacterial infections. According to regulatory documents, this includes certain infections of the urinary tract, middle ear (otitis media), and throat (pharyngitis or tonsillitis). It is also approved for treating acute exacerbations of chronic bronchitis and uncomplicated gonorrhea.

Q: Does Cefi have multiple primary uses according to official documents?

Yes, official documents describe Cefixime as having multiple primary indications. These uses are defined across various body systems, including treating infections of the ear, throat, lungs, urinary tract, and certain types of sexually transmitted infections.

Q: What signs might indicate a serious side effect from Cefi?

Official safety information indicates that serious reactions may be associated with clear physical signs. These signs can include difficulty breathing, severe swelling of the face or throat, blistering and peeling of the skin, or a severe rash. Severe, watery, or bloody diarrhea may also be a sign of a serious condition.

Q: Does taking Cefi affect mental clarity or cause drowsiness?

Regulatory documents report nervous system effects such as headache and dizziness as potential side effects. Less commonly reported effects in official sources include confusion and seizures. There is no directive statement about drowsiness or mental clarity loss as a common effect.

Q: Is there a high risk of allergic reaction with Cefi?

Official texts document that hypersensitivity reactions, including severe allergic reactions, have been reported with this medicine. Regulatory information notes that cross-hypersensitivity with penicillins is possible. This may occur in up to 10% of patients who have a known penicillin allergy.

Q: Does Cefi affect energy levels or cause feelings of fatigue?

According to official safety documents, general tiredness and weakness are listed as less common potential adverse effects of the medicine. These are documented side effects based on clinical and post-marketing surveillance.

Q: Can Cefi be used by older adults?

Cefixime is generally indicated for use in the adult population. Official clinical data indicate that the drug's concentration in the body does not show significant differences between younger and older subjects. Dosage adjustments are officially defined for all adult patients with kidney function impairment, regardless of age.

Q: How quickly should a person expect to notice the effects of Cefi?

The onset of clinical effect can vary between individuals and infections. However, regulatory documents state that Cefixime reaches its peak concentration in the bloodstream approximately 4 hours after being taken orally.

Q: How long does Cefi stay in the body after the last administration?

The time it takes for the concentration of the medicine in the body to be reduced by half—known as the elimination half-life—is documented in regulatory texts to be approximately 3 to 4 hours.

Q: Can Cefi stop working effectively if used over a long period?

Official safety information states that superinfection—the overgrowth of non-susceptible organisms—may occur following a prolonged course of therapy. Additionally, research notes that reduced bacterial susceptibility is a factor that requires continuous monitoring of the medicine's performance.

Q: How is Cefi different from other similar medicines that treat the same condition?

Cefixime is officially classified as a third-generation cephalosporin antibiotic. This classification, as described in regulatory documents, signifies its improved stability against certain bacterial enzymes when compared to some earlier generation cephalosporins.

Q: Are there any ongoing studies about new applications or patient groups for Cefi?

Regulatory documents highlight the necessity of continuous monitoring of Cefixime's performance due to the ongoing pattern of reduced bacterial susceptibility observed in research. This monitoring is required, though official labels may not specify details of currently running trials for new applications.

Q: What are the official 'use conditions' for Cefi?

The official 'use conditions' refer to the specific infections the medicine is approved to treat. This list includes uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea.

Q: Is Cefi considered appropriate for long-term management of chronic conditions?

Regulatory documents do not contain data establishing the long-term effects of Cefixime through clinical trials. The medicine is primarily prescribed for defined, limited durations for acute bacterial infections.

Q: Why is Cefi prescribed for certain infections but not others?

Cefixime is officially classified as a bactericidal agent intended to act against a specific range of susceptible bacteria. Regulatory guidelines define that Cefixime is intended to be used only to treat infections proven or strongly suspected to be caused by these specific susceptible organisms.

Q: What does it mean if Cefi has a specific safety classification?

Cefixime is classified as a prescription-only medicine and an antibiotic in the third-generation cephalosporin class. This classification signifies its specific spectrum of activity and stability against certain bacterial enzymes. It is also classified as a bactericidal agent, meaning it acts by directly killing susceptible bacteria.

Q: Does the mechanism of action for Cefi differ significantly from older drugs?

Yes, Cefixime is officially classified as a third-generation cephalosporin, which is clinically recognized in regulatory documents for having improved stability against certain bacterial enzymes when compared to some earlier generation cephalosporins.

How should Cefi be stored and disposed of?

Storage and Stability Requirements

Storage of Cefixime (Cefi) must strictly adhere to the conditions outlined in the official regulatory label.

Dosage Form Temperature and Environmental Requirements
Tablets and Dry Powder Store at Controlled Room Temperature (20 C to 25 C). The product must be protected from light and moisture.
Reconstituted Suspension May be stored at room temperature or under refrigeration. Do not allow the suspension to freeze.

The medicine must be kept in its original, tightly closed container at all times. The liquid suspension has a stability period of 14 days after mixing, after which the unused portion must be discarded. All forms of Cefixime must be kept out of the sight and reach of children and pets.

Official Disposal Instructions

Unused or expired Cefixime should be disposed of via an authorized drug take-back program. If a program is unavailable, follow federal guidelines by mixing the medicine with an undesirable substance (such as dirt or coffee grounds) and sealing it in a container before discarding it in the household trash. The product should not be flushed down a toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cefi found in:

A-Z Index: